Products for Research Use Only

2-Methoxycinnamaldehyde

CAT: 0804-HY-W046353-01Size: 100 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-W046353-01Size:100 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
2-Methoxycinnamaldehyde (o-Methoxycinnamaldehyde) is a natural compound that can be isolated from Cinnamomum cassia. 2-Methoxycinnamaldehyde inhibits topoisomerase-I/II and NF-κB signaling pathway, causes mitochondrial dysfunction, induces lysosomal vesiculation, thereby leading to DNA damage and cell apoptosis. 2-Methoxycinnamaldehyde exhibits antitumor effects[1][2][3].
CAS Number
1504-74-1
Product Name Alternative
O-Methoxycinnamaldehyde
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
Apoptosis; Caspase; Mitochondrial Metabolism; NF-κB; Topoisomerase
Type
Natural Products
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; NF-κB
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/2-methoxycinnamaldehyde.html
Purity
98.95
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C/C=C/C1=CC=CC=C1OC
Molecular Formula
C10H10O2
Molecular Weight
162.19
Precautions
H315, H319, H335
References & Citations
[1]Wong HY, et al. Cinnamomum verum Component 2-Methoxycinnamaldehyde: A Novel Anticancer Agent with Both Anti-Topoisomerase I and II Activities in Human Lung Adenocarcinoma A549 Cells In Vitro and In Vivo. Phytother Res. 2016 Feb;30 (2) :331-40.|[2]Liu YH, et al. Cinnamomum verum ingredient 2-methoxycinnamaldehyde: a new antiproliferative drug targeting topoisomerase I and II in human lung squamous cell carcinoma NCI-H520 cells. Eur J Cancer Prev. 2017 Jul;26 (4) :314-323.|[3]Jin YH, et al. 2-Methoxycinnamaldehyde inhibits the TNF-α-induced proliferation and migration of human aortic smooth muscle cells. Int J Mol Med. 2017 Jan;39 (1) :191-198.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, stored under nitrogen)
Scientific Category
Natural Products
Clinical Information
No Development Reported